Evaluation the Role of Hepcidin and Alkaline Phosphatasein the Blood of Breast Cancer Women

Abstract

Breast cancer is a common malignancy and a major cause of death in women. In 2015, 570,000 women died from breast cancer that is approximately 15% of all cancer deaths among women. The goal of this study was to examine the changes in hepcidin, and alkaline phosphatase (ALP) in women with breast cancer concerning its validity for the early detection and the severity of the disease. A cross sectional study was carried out in Kirkuk City from November 2022 to March 2023. The number of breast cancer women under study was 60 whose ages were between 30 - 70 years old. These women were consisting Kirkuk Oncology Cancer. The control group included 30 healthy women and their ages were between 30 - 70 years old, women with breast cancer were collected from Kirkuk Oncology Center. The body weight and height were measured for the calculation of the body mass index. This study showed that the peak age of women with breast cancer was between 45 – 56 years and its percentage was 40%, while the least age group 35-44 years, and its percentage which was found to be 27 %. Also this study shows that the mean of BMI was number of breast cancer, were 7(12%) women underweight (<18.5), 10(17%) women normal weight (18.5 – 24.9), 20 (33%) overweight (25 – 29.9), and 23 (38%) with obese (≥ 30). The blood samples were collected from each women included in this study for the estimation ALP and Hepcidin (HP). This study aims to assess the role of Hepcidin in women with breast cancer and to investigate the correlation between ALP. The mean of the serum level of Alkaline Phosphatase (ALP) in breast cancer women comparing with the control group (95.2 ± 59.0 versus 82.4 ±37.4 U/L). The result was no significant (p<0.215).